The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive gains, the expiration of its exclusive rights opened the door to off-brand https://esmeerbdh285202.blogdeazar.com/42174864/sildenafil-and-pharma-a-risky-investment